SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the quarterly period ended March 31, 2002.

       OR

[ ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the transition period from                    to
                                      ------------------    ------------------

       Commission file number

                          Bio-Medical Automation, Inc.
                          ----------------------------
       (Exact name of small business issuer as specified in its charter.)

        Colorado                       0-16335             84-0922701
        --------                       -------             ----------
(State or other jurisdiction      (Commission File        (IRS Employer
     of incorporation)                 Number)          Identification No.)


                 10 South Street, Ste. 202, Ridgefield, CT 06877

                                 (203) 894-9755
                                 --------------
                           (Issuer's telephone number,
                              including area code)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes   X           No
   -------          -------

As of May 17, 2002 the Registrant had outstanding 813,028 shares of common
stock, par value $.10

Transitional Small Business Disclosure Format (check one):
Yes               No   X
   -------          -------

<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                   FORM 10-QSB
                                 MARCH 31, 2002



                                                                       Page

PART I - FINANCIAL INFORMATION                                           3

Item 1.  Financial Statements                                            3

         Balance Sheets as of December 31, 2001 and
                  March 31, 2002 (unaudited)                             3

         Statements of Operations for the Three Months Ended
                  March 31, 2001 and 2002, Cumulative Amounts from
                  January 1, 2000 through March 31, 2002 (unaudited)     4

         Statements of Cash Flows for the Three Months Ended
                  March 31, 2001 and 2002, Cumulative Amounts from
                  January 1, 2000 through March 31, 2002 (unaudited)     5

         Notes to Financial Statements                                   6


Item 2.  Management's Plan Of Operations                                 7

PART II - OTHER INFORMATION                                              9

Item 5.  Other Information                                               9

Item 6.  Exhibits & Reports on Form 8-K                                  9

SIGNATURES                                                               9

<PAGE>

                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements.

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                       December 31,   March 31, 2002
                                                                           2001         (Unaudited)
<S>                                                                    <C>              <C>
                                                 ASSETS
CURRENT ASSETS
    Cash                                                               $   341,611      $   335,440
    Interest receivable - officer                                            2,262            3,012
                                                                       -----------      -----------

        Total Current Assets                                               343,873          338,452
                                                                       -----------      -----------

                                                                       $   343,873      $   338,452
                                                                       ===========      ===========


                                    LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses                              $     7,679      $    12,289
                                                                       -----------      -----------

        Total Current Liabilities                                            7,679           12,289
                                                                       -----------      -----------


STOCKHOLDERS' EQUITY
    Preferred Stock, $.10 par value; authorized - 1,000,000 shares
           Issued - none
    Common Stock, $.10 par value; authorized - 5,000,000 shares
           Issued and outstanding - 813,028 shares                          81,303           81,303
    Capital in excess of par value                                       1,464,884        1,464,884
    Note receivable - officer                                              (50,000)         (50,000)
    Stock issued for deferred compensation                                 (11,000)              --
    Accumulated (deficit)                                                 (947,820)        (947,820)
    (Deficit) accumulated during the development stage                    (201,173)        (222,204)
                                                                       -----------      -----------

                                                                           336,194          326,163
                                                                       -----------      -----------

                                                                       $   343,873      $   338,452
                                                                       ===========      ===========
</TABLE>
                 See accompanying notes to financial statements.

                                        3
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS

                                                                  Cumulative
                                       Three Months Ended        Amounts from
                                            March 31,        January 01, 2000 to
                                       2001           2002        March 31, 2002
REVENUES
      Interest income               $   1,750      $   1,579      $  15,473
                                    ---------      ---------      ---------


OPERATING EXPENSES
    General and Administrative         24,030         22,610        218,953
    Patent write-off                       --             --         18,724
                                    ---------      ---------      ---------
                                       24,030         22,610        237,677
                                    ---------      ---------      ---------


NET (LOSS)                          $ (22,280)     $ (21,031)     $(222,204)
                                    =========      =========      =========

NET (LOSS) PER COMMON SHARE
    Basic and Diluted               $   (0.03)     $   (0.03)     $    (.30)
                                    =========      =========      =========

WEIGHTED AVERAGE NUMBER OF
    COMMON SHARES OUTSTANDING -
    Basic and Diluted                 707,783        813,023        740,372
                                    =========      =========      =========






                 See accompanying notes to financial statements.

                                        4
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                              Cumulative
                                                                     Three Months Ended      Amounts from
                                                                          March 31,       January 01, 2000 to
                                                                     2001           2002     March 31, 2002
<S>                                                               <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITES
        Net income (loss)                                         $ (22,280)     $ (21,031)     $(222,204)
        Adjustment to reconcile net income (loss) to net cash
            provided (used) by operating activities
             Stock issuance for salary                               12,000         11,000         96,000
             Stock issued for professional services                      --             --         18,200
             Write-off of patent                                         --             --         18,724
             Changes in assets and liabilities
                  (Increase) in interest receivable                      --           (750)        (3,012)
              Increase (decrease) in accounts payable and
                    accrued expenses                                  6,077          4,610         (3,105)
                                                                  ---------      ---------      ---------

        Net Cash (Used) by Operating Activities                      (4,203)        (6,171)       (95,397)
                                                                  ---------      ---------      ---------

CASH FLOWS FROM INVESTING ACTIVITIES

        Net Cash (Used) in Investing Activities                          --             --             --
                                                                  ---------      ---------      ---------

CASH FLOWS FROM FINANCING ACTIVITIES
             Exercise of common stock warrants                           --             --          5,625
                                                                  ---------      ---------      ---------

        Net Cash Provided by Financing Activities                        --             --          5,625
                                                                  ---------      ---------      ---------

NET INCREASE (DECREASE) IN CASH                                      (4,203)        (6,171)       (89,772)

CASH, BEGINNING OF PERIODS                                          360,741        341,611        425,212
                                                                  ---------      ---------      ---------

CASH, END OF PERIODS                                              $ 356,538      $ 335,440      $ 335,440
                                                                  =========      =========      =========
</TABLE>

                 See accompanying notes to financial statements.

                                        5
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                        THREE MONTHS ENDED MARCH 31, 2002

         The unaudited financial statements included herein were prepared from
the records of the Company in accordance with Generally Accepted Accounting
Principles and reflect all adjustments which are, in the opinion of management,
necessary to provide a fair statement of the results of operations and financial
position for the interim periods. Such financial statements generally conform to
the presentation reflected in the Company's Form 10-KSB filed with the
Securities and Exchange Commission for the year ended December 31, 2001. The
current interim period reported herein should be read in conjunction with the
Company's Form 10-KSB subject to independent audit at the end of the year.

         The results of operations for the three months ended March 31, 2002 are
not necessarily indicative of the results that may be expected for the year
ending December 31, 2002.


NOTE 1. COMMON STOCK

         In 2001, the Company issued 38,400 shares of common stock (valued at $
1.25 per share) to its President for services to be rendered to the Company for
the period of March 25, 2001 through March 24, 2002. Compensation expense to the
Company is recorded as the shares are earned. Unearned shares are shown in the
accompanying 2001 financial statement as stock issued for deferred compensation.

NOTE 2. NOTE RECEIVABLE - OFFICER

         In 2001, the Company loaned the President $50,000 at 6.0%, due March
30, 2003, to exercise warrants to purchase 50,000 shares of the Company's common
stock at $1.00 per share.


                                       6
<PAGE>

Item 2.  Management Discussion and Analysis and Plan of Operations

         The following discussion and analysis provides information which the
Company's management believes to be relevant to an assessment and understanding
of the Company's results of operations and financial condition. This discussion
should be read together with the Company's financial statements and the notes to
financial statements, which are included in this report, as well as the
Company's Form 10-KSB for the year ended December 31, 2001.

         Bio-Medical Automation, Inc. was incorporated as a Colorado corporation
on October 13, 1983 under the name OZO Diversified Automation, Inc. In March
1999, in connection with the sale of substantially all of the Company's assets
the Company changed its name to Bio-Medical Automation, Inc. ("BMA" or the
"Company").

         The Company has suspended all operations, except for necessary
administrative matters relating to the timely filing of periodic reports as
required by the Securities Exchange Act of 1934. Accordingly, during the three
months ended March 31, 2002 and the year ended December 31, 2001, the Company
has earned no revenues from operations.

         The Company's management is seeking to arrange for a merger,
acquisition, business combination or other arrangement by and between the
Company and a viable operating entity. The Company has not identified a viable
operating entity for a merger, acquisition, business combination or other
arrangement, and there can be no assurance that the Company will ever
successfully arrange for a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity.

         The Company anticipates that the selection of a business opportunity
will be a complex process and will involve a number of risks, because
potentially available business opportunities may occur in many different
industries and may be in various stages of development. Due in part to depressed
economic conditions in a number of geographic areas, rapid technological
advances being made in some industries and shortages of available capital,
management believes that there are numerous firms seeking either the limited
additional capital which the Company will have or the benefits of a publicly
traded corporation, or both. The perceived benefits of a publicly traded
corporation may include facilitating or improving the terms upon which
additional equity financing may be sought, providing liquidity for principle
shareholders, creating a means for providing incentive stock options or similar
benefits to key employees, providing liquidity for all shareholders and other
factors.


                                       7
<PAGE>



         In some cases, management of the Company will have the authority to
effect acquisitions without submitting the proposal to the shareholders for
their consideration. In some instances, however, the proposed participation in a
business opportunity may be submitted to the shareholders for their
consideration, either voluntarily by the Board of Directors to seek the
shareholders' advice and consent, or because of a requirement of state law to do
so.

         In seeking to arrange a merger, acquisition, business combination or
other arrangement by and between the Company and a viable operating entity,
management's objective will be to obtain long-term capital appreciation for the
Company's shareholders. There can be no assurance that the Company will be able
to complete any merger, acquisition, business combination or other arrangement
by and between the Company and a viable operating entity.

         The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

Results of Operations
---------------------

         For the three months ended March 31, 2002, the Company has not earned
any revenues, except for interest income of $1,579. For the same period the
Company incurred general and administrative expenses of $22,610 resulting in a
net loss from operations equal to $21,031. General and administrative
expenditures were and have been directed to maintaining the Company's status as
a public company, including (without limitation) filing reports with the
Securities and Exchange Commission.

Liquidity and Capital Resources
-------------------------------

         During three months ended March 31, 2002, the Company satisfied its
working capital needs from cash on hand at the beginning of the quarter and cash
generated from interest income during the quarter. As of March 31, 2002, the
Company had on hand cash in the amount of $335,440.

         The Company's future financial condition will be subject to its ability
to arrange for a merger, acquisition or a business combination with an operating
business on favorable terms that will result in profitability. There can be no
assurance that the Company will be able to do so or, if it is able to do so,
that the transaction will be on favorable terms not resulting in an unreasonable
amount of dilution to the Company's existing shareholders.

         The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

                                       8
<PAGE>

         Except for historical information contained herein, the statements in
this report are forward-looking statements that are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. You
can identify these forward-looking statements when you see words such as
"expect," "anticipate," "estimate," "may," "believe," and other similar
expressions. These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Actual results could differ materially from those projected in the
forward-looking statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially, from forecasted results. These and other risks are
described elsewhere herein and in the Company's other filings with the
Securities and Exchange Commission, namely the Company's Form 10-KSB for the
year ended December 31, 2001.


                           PART II - OTHER INFORMATION


Item 5.  Other Information

     On March 26, 2002, the Board of Directors of the Company extended Steven N.
Bronson's Employment Agreement to serve as the President of the Company for the
period March 25, 2002 through March 24, 2003. The terms of such Employment
Agreement include the following:

Name                       Title        Salary/Year        Term
-----------------------------------------------------------------

Steven N. Bronson     CEO & President     $48,000         1 year


Item 6.  Exhibits and Reports on Form 8-K

         a)  Exhibits

             None.

         b)  The Company did not file any current reports on Form 8-K during the
             quarter ended March 31, 2002.


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


Dated:  May 20, 2002


                                   BIO-MEDICAL AUTOMATION, INC.


                                   By: /s/ Steven N. Bronson
                                       ------------------------------------
                                       Steven N. Bronson, President
                                       (Principle Executive Officer),
                                       as Registrant's duly authorized officer



                                       9